Publication details
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
Authors | |
---|---|
Year of publication | 2020 |
Type | Article in Periodical |
Magazine / Source | Lancet |
MU Faculty or unit | |
Citation | |
Web | https://www.sciencedirect.com/science/article/pii/S0140673620322923?via%3Dihub |
Doi | http://dx.doi.org/10.1016/S0140-6736(20)32292-3 |
Description | Selinexor combined with dexamethasone has shown activity in patients with heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor with bortezomib (a proteasome inhibitor) and dexamethasone induced high response rates with low rates of peripheral neuropathy, the main dose-limiting toxicity of bortezomib. We aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and dexamethasone versus standard bortezomib and dexamethasone in patients with previously treated multiple myeloma. |